NEW YORK — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced today it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for its proprietary hemostatic gel technology. This follows Cresilon’s successful launch of VETIGEL®, its revolutionary hemostatic gel for the animal health market.
“This FDA submission marks an important milestone for Cresilon in our commitment to significantly improve the standard of care in wound treatment,” said Joe Landolina, CEO of Cresilon. “Cresilon’s mission is to save lives, and we are eager for our technology to be permitted to make a significant positive impact in the human health market, just as we are already doing in the animal health market.”
Cresilon Hemostatic GelTM, the subject of Cresilon’s FDA submission, is a hemostatic gel for external use only. It is intended to be easy-to-use, non-animal derived, and to rapidly control bleeding. Cresilon expects this combination of attributes will allow the product to uniquely address critical unmet needs in the human health market.
“We see a significant opportunity for our technology in the human market, and this FDA submission is Cresilon’s first step towards seizing that opportunity,” said Joe Landolina. “We look forward to working through the FDA review process to obtain clearance for Cresilon Hemostatic Gel.”
About Cresilon, Inc.
Cresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company’s proprietary gel technology. The company’s technology has revolutionized the current standard of care in hemostasis and wound treatment with product lines targeting both the human and animal health markets. Cresilon’s mission is to save lives. Learn more at http://www.cresilon.com.
Subscribe to our Newsletter
Stay in touch with us to get Cresilon’s latest news, investment opportunities, and product releases.